Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YQYiHua QiuSKSteven M. Kornblau

Discussion

Loading...

Member takes

Overview

Low wilms tumor 1 protein expression worsens prognosis in acute myelogenous leukemia, indicating the need for careful treatment planning.

Key Points

  • To evaluate the prognostic significance of wild-type wilms tumor 1 (WT1) protein levels in acute myelogenous leukemia (AML).
  • Measured protein levels using Reverse Phase Protein Arrays in AML samples
  • Analyzed patient outcomes based on WT1 mutation and protein levels
  • Utilized Cox proportional hazards models for survival analysis
  • Low WT1 protein expression correlates with poor prognosis and chemoresistance in AML
  • High WT1 expression linked to improved overall survival with different treatments
  • Differential expression of specific proteins suggests potential therapeutic pathways.

Cite This Study

Qiu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3b5https://doi.org/10.1182/blood-2025-5271
View Full Paper
Ask AI
Bookmark
Share